Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal
Repligen Corp. plans to acquire BioLife Solutions Inc. in a $1.5B deal, subject to regulatory and stockholder approvals, expected to close in Q4. Consideration is 64% Repligen stock and 36% cash, valuing BioLife at $11.25/share cash plus 0.1442 shares, about $31/share. Repligen FY2025 revenue was $738.3M; BioLife FY2025 revenue $96.2M.
How this was made
The 30-second read
Why it matters
The article provides concrete M&A terms (value, consideration mix, per-share cash equivalent) and a Q4 closing window, enabling traders to model deal-spread and approval-risk scenarios for both RGEN and BLI.
Market read
This is a first-report, deal-specific catalyst with defined consideration and timing, directly relevant for merger-arb positioning and approval-risk hedging.
What to watch
Regulatory approval and BioLife stockholder approval are explicit gating items; any delay can extend merger-arb duration and increase carry and volatility.
Background
Repligen is a bioprocessing technology provider; BioLife supplies cell-processing tools and services, including CryoStor biopreservation media used across cell-therapy workflows.
Ticker impact
Repligen announced it will acquire BioLife Solutions for about $1.5B, with 64% stock and 36% cash, expected to close in Q4.
Near-term trading likely follows deal-spread dynamics and regulatory/stockholder approval expectations into Q4.
The article discloses the headline transaction value, consideration mix, per-share cash value, and the Q4 closing timeline, which directly drive merger-arb and risk pricing.
Market effects
Strengthens consolidation in bioprocessing and cell-therapy workflow consumables, potentially signaling continued M&A appetite in enabling technologies.
Highlights Washington-state biotech manufacturing footprint (Bothell/Woodinville) tied to cell-therapy supply chain.
Deal narrative emphasizes Asia Pacific commercial reach, which may influence competitive positioning for cell-therapy tooling providers.
Counterpoint
The stock component (64%) can dilute or introduce market-risk if RGEN’s share price moves materially before closing, widening the deal spread.
Key entities
- acquirerRepligen Corp.
Life-sciences bioprocessing technology company planning to acquire BioLife Solutions in a $1.5B deal.
- targetBioLife Solutions Inc.
Cell-processing tools and services developer and supplier for the cell- and gene-therapy market, being acquired.
- product/franchiseCryoStor
BioLife’s biopreservation media platform supporting multiple approved therapies and trials, cited as a key differentiator.
